Boston Partners
HAE icon

Boston Partners’s Haemonetics HAE Stock Holding History

Boston Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4M Sell
405,892
-150,787
-27% -$9.69M 0.03% 339
2026
Q1 		$31.4M Buy
556,679
+234,012
+73% +$15.2M 0.03% 318
2025
Q4 		$25.8M Sell
322,667
-248,224
-43% -$16.7M 0.03% 348
2025
Q3 		$28M Buy
570,891
+27,722
+5% +$1.72M 0.03% 332
2025
Q2 		$40.7M Buy
543,169
+11,738
+2% +$777K 0.05% 271
2025
Q1 		$33.4M Sell
531,431
-4,831
-0.9% -$329K 0.04% 266
2024
Q4 		$41.5M Buy
536,262
+115,506
+27% +$9.28M 0.05% 253
2024
Q3 		$33.5M Sell
420,756
-4,250
-1% -$343K 0.04% 270
2024
Q2 		$35.7M Sell
425,006
-19,174
-4% -$1.69M 0.04% 265
2024
Q1 		$38.3M Sell
444,180
-263,254
-37% -$20.7M 0.05% 267
2023
Q4 		$60.4M Sell
707,434
-24,168
-3% -$2.09M 0.08% 237
2023
Q3 		$65.1M Sell
731,602
-27,990
-4% -$2.5M 0.09% 228
2023
Q2 		$65.1M Buy
759,592
+95,928
+14% +$8.11M 0.09% 218
2023
Q1 		$54.9M Buy
663,664
+147,440
+29% +$11.9M 0.08% 219
2022
Q4 		$41M Buy
516,224
+216,210
+72% +$17.4M 0.06% 231
2022
Q3 		$22.6M Sell
300,014
-9,006
-3% -$647K 0.03% 280
2022
Q2 		$20.3M Buy
309,020
+5,495
+2% +$325K 0.03% 308
2022
Q1 		$19.1M Buy
303,525
+2,937
+1% +$160K 0.02% 326
2021
Q4 		$15.9M Sell
300,588
-4,621
-2% -$282K 0.02% 335
2021
Q3 		$21.5M Sell
305,209
-2,273
-0.7% -$143K 0.03% 316
2021
Q2 		$20.4M Buy
+307,482
New +$21.8M 0.03% 320
2018
Q3 		– Sell
-20,005
Closed -$1.79M – 736
2018
Q2 		$1.79M Buy
+20,005
New +$1.69M ﹤0.01% 676

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's HAE Position: Q2 2026 in Review

Boston Partners reduced its Haemonetics (HAE) stake by 27% in Q2 2026, selling an estimated $9.69M and leaving 405,892 shares worth $30.4M. The position accounts for 0.03% of the portfolio, ranked #339.

Boston Partners first reported a position in HAE in Q2 2018 and has held it in 22 quarters since. The position peaked at $65.1M in Q2 2023. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Boston Partners held 405,892 shares of Haemonetics worth $30.4M as of Q2 2026.
  • Boston Partners sold 150,787 Haemonetics shares in Q2 2026, an estimated $9.69M.
  • Haemonetics made up 0.03% of Boston Partners's portfolio in Q2 2026, its #339 holding.
  • Boston Partners first reported a position in Haemonetics in Q2 2018 and has held it in 22 quarters since.
  • Boston Partners's Haemonetics position peaked at $65.1M in Q2 2023.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.